Abstract. Nanostructured copper-doped uorapatite (Cu x .Ca (10 x) .(PO 4 ) 6 .F 2 ) having crystallite sizes of 19, 29, and 34 nm at x = 0:9, 0.4, and 0.0, respectively, was synthesized by planetary ball milling of CaO, P2O5, CaF2, and CuO powders. Speci cations of the products were determined by Fourier-transform infrared spectroscopy, eld emission scanning electron microscopy, transmission electron microscopy, and X-ray di raction analyses. In-vitro studies and Mossman's Tetrazole Test (MTT) assays were also conducted by incubating Cu x .Ca (10 x) .(PO 4 ) 6 .F 2 powder into Kokubo's Simulated Body Fluid (SBF) and against BT-20 cell, respectively, to determine bioactivity and biocompatibility of the materials. Antibacterial e ects on Staphylococcus aureus were assessed by the disc di usion test method. Measurements showed that the rate of formation of uorapatite was lowered by Cu content. Besides, in-vitro experiments showed the same SBF interacted apatite precipitation for all samples. In contrast, MTT assays revealed di erent behavior for pure uorapatite and apatite with x = 0:9 Cu against BT-20 cell after 24 h of incubation. This highlights the increase of uorapatite cytotoxicity when Cu ion is present in the apatite structure. Copper-doped uorapatite was, however, desirably antibacterial. This stemmed from copper ions interactions with the bacterial metabolism which resulted in enzymes neutralization and copper-doped uorapatite antibacterial behavior.